EUCTR2011-005002-30-IE进行中（未招募）不适用
Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer. - Phase II Lap/Epi, ICORG 09-13
ICORG-the All Ireland co-operative Oncology Research group0 个研究点目标入组 46 人开始时间: 2011年11月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Ability to understand and has signed a written informed consent document prior to any study related procedures.
- •2.Female patients age= 18 years
- •3.ECOG Performance Status of = 2
- •4.Histologically or cytologically-confirmed invasive breast cancer with Stage IV disease (metastatic breast cancer)
- •5.Patients must have measurable disease according to RECIST 1.1 criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.
- •6.HER2-positivity defined as IHC score of 3+ or ratio of HER2 gene signals to centromere 17 (Cep17) signals =2.0 by fluorescent in situ hybridization (FISH).
- •7.TopoII alpha amplification defined as a ratio of TopoIIa gene signals to centromere 17 signals =1.5 by in situ hybridisation.
- •8.Cardiac ejection fraction within the institutional range of normal as measured by MUGA or ECHO.
- •9.Adequate haematological, hepatic, and renal function.
- •Haemoglobin = 9g/dL.
- •Absolute granulocyte count =1.5 x 10^9/L.
- •Platelets = 100 x 10^9/L.
- •Total bilirubin =ULN of the treating institution, unless the patient has a documented history of congenital hyperbilirubinemia (Gilbert's syndrome).
- •Both ALT and AST = 3 x ULN with or without liver metastases.
- •Alkaline phosphatase = 2.5 x ULN.
- •Calculated creatinine clearance (CrCl) = 40mL/min according to the formula of Cockcroft and Gault
- •10.women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Acceptable methods of birth control:
- •Complete abstinence from intercourse from the time of the screening pregnancy test until 28 days after the final dose of lapatinib; or
- •Consistent and correct use of one of the following acceptable methods of birth control:
- •Male partner who is sterile prior to the female patient’s entry into the study and is the sole sexual partner for that female patient; or
- •Any intrauterine device (IUD) with a documented failure rate of less than 1% per year; or
- •Barrier methods (e.g. condoms, diaphragms, caps) only if used in combination with one of the above acceptable methods.
- •11.Life expectancy greater than 12 weeks
- •12.Patients may receive bisphosphonates where they are clinically indicated if started prior to first study treatment administration.
- •13.Patients with a history of any of the following cancers are eligible if diagnosed and treated longer than 5 years: cervical carcinoma in situ, melanoma in situ, and basal cell or squamous cell carcinoma of the skin;
- •14.Are able to swallow and retain oral medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Untreated and uncontrolled central nervous system (CNS) metastases. Patients with known CNS metastases are eligible if metastases are treated and proven stable for at least 3 months (asymptomatic and not receiving steroids). CNS metastases cannot be used as target lesions to assess objective response
- •2.Prior anthracycline or anthracenedione therapy (Prior- non-anthracycline adjuvant therapy is NOT an exclusion criterion)
- •3.No prior chemotherapy and/or trastuzumab for metastatic breast cancer. Prior adjuvant trastuzumab is allowed (provided at least 3 months has elapsed from the most recent trastuzumab infusion). No prior other therapy with ErbB inhibitors is allowed. Subjects who have acute or currently active /requiring anti-viral therapy hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •4.Uncontrolled or symptomatic angina, arrhythmias, congestive heart failure or other cardiac disorders.
- •5.Evidence of or history of QT (QTc) interval above 470msec
- •6.Patients with elevated troponin I (TNI)
- •7.Immediate or delayed hypersensitivity or untoward reaction to lapatinib, epirubicin or other related compounds, or to drugs chemically related to lapatinib (including other anilinoquinazolines, e.g. gefitinib (Iressa) and erlotinib (Tarceva), or other chemically-related compounds).
- •8.Pregnant women are excluded from this study. (breastfeeding should be discontinued if the mother is treated with lapatinib).
- •9.Have unresolved or unstable grade = 2 toxicity from administration of prior cancer treatment
- •10.Prior lapatinib treatment. Patients who received lapatinib in the adjuvant or neo-adjuvant setting as part of a clinical trial are NOT eligible,
- •11.Prior investigational drugs within the past 30 days
- •12.Concurrent treatment with prohibited medications (refer to Section 7.5 for details on prohibited medications)
- •13.Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s, ulcerative colitis).
- •14.Have a concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical disorder that would interfere with the patient safety;
- •15.Have an active or uncontrolled infection;
- •16.Have dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;
- •17.HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with lapatinib.
研究者
相似试验
进行中（未招募）
1 期
A study in HER2-positive breast cancer that has spread and has not responded to a course of anti-cancer treatment and a study in HER2-positive gastric cancer that has spread and has not been treated with any chemotherapeutic agent before.Her2 postive metastatic breast cancer and Her2 positive locally advanced or metastatic gastric cancer.MedDRA version: 14.1Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001547-46-ESF. Hoffmann-La Roche Ltd146
进行中（未招募）
1 期
A study in HER2-positive breast cancer that has spread and has not responded to a course of anti-cancer treatment and a study in HER2-positive gastric cancer that has spread and has not been treated with any chemotherapeutic agent before.EUCTR2012-001547-46-FRF. Hoffmann-La Roche Ltd146
进行中（未招募）
不适用
An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment - RAD001 and NETs, first line treatmentPatients with neuroendocrine tumoursMedDRA version: 9.1Level: LLTClassification code 10057270Term: Neuroendocrine carcinomaEUCTR2008-007153-13-ITI.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY
招募中
2 期
Phase 2 platform study of combination therapy with pimitespib in patients with malignant tumorsCRPC cohortMetastatic castration-resistant prostate cancerJPRN-jRCT2031230263Sato Atsushi32
进行中（未招募）
不适用
A Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed in Patients with Advanced or Metastatic Non-small Cell Lung Cancer - NDAdvanced or metastatic non-squamous second-line Non-small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10029521MedDRA version: 9.1Level: LLTClassification code 10029522EUCTR2009-013787-39-ITEli Lilly and company55